Analyst
Rodman & Renshaw
Equibles does not estimate personal net worth.
Michael King is recorded as Analyst at Rodman & Renshaw. Michael King has spoken on 2 earnings calls and 1 other investor event across 3 companies, most recently for OmniAb, Inc. on August 6, 2026. Those appearances were for OmniAb, Inc. (OABI), Elicio Therapeutics, Inc. (ELTX) and Karyopharm Therapeutics Inc. (KPTI). The companies whose calls Michael King spoke on are classified in the Healthcare sector.
“One is, even though with the raised revenue guidance, you guys are still facing the 20 plus million dollar gap between your spend and the expected revenues. So I just wonder how we should think about how you're going to close that gap.”
“You know, I know you've stated a couple times that the study didn't achieve its primary endpoint, and while that may be true, I think your remarks about hypothesis validation are certainly spot on.”
“I'm just wondering, the data that we'll see at ASCO, how closely is that going to map?”
Rodman & Renshaw
Analyst
Transcript header (unverified)
OABI
Biotechnology · Healthcare
